ly-377604
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT00993421)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Beta-3 adrenergic receptorAGONIST
ADRB3 agonist
Phase 2 study in 2011 terminated.
- Beta-1 adrenergic receptorANTAGONIST
ADRB1 antagonist
Phase 2 study in 2011 terminated.
- Beta-2 adrenergic receptorANTAGONIST
ADRB2 antagonist
Phase 2 study in 2011 terminated.
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(Cc1ccc(Oc2ccc(C(N)=O)cn2)cc1)NC[C@H](O)COc1cccc2[nH]c3ccccc3c12- Mol. weight
- 524.62 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2012520 ↗
Also known as
- ly377604
- ly377604
- ly-377604
- ly-377604
- ly-377604
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00993421 | Phase 2 | Oct 1, 2009 | Eli Lilly |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 1 | 1 | 1 | 2009 |
1 organizations
Page 1 / 1